TriVascular Technologies Inc

TriVascular Technologies — Merger or Acquisition (October 2015)

39 slides from TriVascular Technologies's merger presentation, Oct 27, 2015

  1. Slide 1: TriVascular Employee Presentation

    TriVascular Employee Presentation All Employee Meeting October 26, 2015 Confidential

  2. Slide 2: Today’s announcement

    Today’s announcement Board has approved merger with Endologix TriVascular shareholders will receive stock and cash consideration After closing, new combined entity will continue to market Ovation and legacy products Santa Rosa facility and core functions to remain intact Deal is subject to regulator

  3. Slide 3: Merger rationale

    Merger rationale Offers physicians three clinically proven platforms to customize the therapy for each unique anatomy Dramatically expand global & functional capability ~$190+ million pro forma revenue base Enables faster time to profitability Accelerates growth for OVATION Platform Increases value

  4. Slide 4: Endologix and TriVascular company snapshots

    Endologix and TriVascular company snapshots Location Irvine, CA Santa Rosa, CA Number of employees 614 308 2014 revenue $148 Million $32 Million Commercial reach 44 countries 24 countries Key products AFX, Nellix Ovation

  5. Slide 5: Strong revenue growth with a combined CAGR of 23%

    Strong revenue growth with a combined CAGR of 23% Revenue $millions 200 180 160 32 140 20 100 89 80 148 60 134 40 83 20 52 2009 2010 2011 2012 2013 2014 Endologix TriVascular Sources: Endologix 2014 Annual Report; TriVascular 10-K

  6. Slide 6: Diversified product revenue

    Diversified product revenue (post merger) Total Revenue: $190 million Q4 2014 – Q3 2015 Revenue by product Revenue by geography Ovation 19% U.S. 70% Nellix 13% AFX International 68% 30%

  7. Slide 7: Founder’s Perspective

    ———_— TRIVASCULA R* Founder’s Perspective :

  8. Slide 8: “If you make it clinically relevant, there will always be a path for the business”

    “If you make it clinically relevant, there will always be a path for the business” John B. Simpson, MD

  9. Slide 9: 2002 TV1 “A” (pre-BSC)

    2002 TV1 “A” (pre-BSC)

  10. Slide 10: [graphcies]

    [graphcies]

  11. Slide 11: Is there a Better Way?

    Is there a Better Way? Can it be Made? Will it Work?

  12. Slide 12: Deep pipeline addressing $3B+ opportunity

    Deep pipeline addressing $3B+ opportunity* (post merger) 2015 2016 2017 2018 2019 2020 U.S. CHEVAS Europe THORACIC CHEVAS Asia Pacific (Japan) (Japan) (Japan) (China) (Brazil, Argentina) Latin America CHEVAS (Argentina) (Brazil) *Post-merger estimates based on anticipated regulatory approval timelin

  13. Slide 13: Clinical Perspective

    ———_— TRIVASCULA R* Clinical Perspective :

  14. Slide 14: The only company with multiple AAA treatment options

    The only company with multiple AAA treatment options (post merger) 1 4

  15. Slide 15: Significant clinical evidence to drive adoption

    Significant clinical evidence to drive adoption (post merger) 2015 2016 2017 Ovation IDE/CAP/PAS (2010) 320 320 320 Global Registry (2011) 501 501 501 LIFE (2014) 200 250 250 LUCY (2015) 20 225 225 Total 1,041 1,296 1,296 AFX IDEs (2000) 707 707 707 PEVAR (2010) 192 192 192 LEOPARD (2015) 150 800 80

  16. Slide 16: Commercial Perspective

    ———_— TRIVASCULA R* Commercial Persp

  17. Slide 17: [graphcies]

    [graphcies]

  18. Slide 18: 2010

    2010 = 116 PrPPeTTPPeeTen esate PEPE T Tee eae a eT Peer e eee TTTrTrenennnereseeet TTETTrennentereseeet

  19. Slide 19: 2011

    2011 = 467 PERERERERERER ER ER ERE PEETERETETETETE EEE EE FEET EE ay TETTTTESSSTCPETEETER CETTTTTOSSSCEFT TEESE POT TTE PEPPRPTEEP RETR ATTY TEPER REET MTT ee ee Thee TT Phtnnennettenenttt conta nntttteaees Fehee THTTTERN TTT RRRRREET EETTTTTRNTTT ERR AA EES FEFE4 +

  20. Slide 20: 2012

    2012 = 755 PREERERTERE ERATE REET FEETT ERATE ERE ETTT TEE FEAF EEE EEE EEE EEE PEEEEEEEREEE ETRE ER FEERTERETTEEEEAER ERE AERERE AERA AREER EARS PREREEERERTERERERERT PEEETETETERERERER TET FAG EEAER ERE E ROR E REE PREPEEEEEETERERER ERE PEEEEEEETERERERER TET AAERAA AER TREE REET EE PREEREEERTERERERE

  21. Slide 21: Hetherenennnennattee ttttHenenneNNttTT + +

    Hetherenennnennattee ttttHenenneNNttTT + + Hennereeennnenntenes snnneenennnentttttt SEeetaeeeeeseeess Sepeheeseeeseeetest HEHHERHREENNNANTETEE NNNEHHRRENNTNNATHEEE FER RR RETR REE E EERE ETD FeEEE EERE ESTER EEE EEE TEHHERERRENDNNNTETEE NNNEHHHERANTNNNTHNEE FERRER EER REESE ER EEED Geter eReEEE EERE

  22. Slide 22: 2014

    2014 = 2,522 THReTtHitnti ttre tnnreTtttHnnHnettT tnntRETHHNNTR REET eeeR ERE ER ERE EE EEE eE ceeeeeeeneEeeEeoeee denennenennnnnnnees teerentttnnanetents ennnenentttttinnttT sees eee en eee eesetees eeeeeeoneoteseees deneenenennnnaniees tenenntnnnnetenes rnneeenentttttinnttT eee ee een ee ee settee

  23. Slide 23: 2015

    2015 = 3,200 pessntuuuuusiiaii} Seetnntnnttnttentint tenttententnnttnntte tentintnttettitttet eeeeee ee eeeeeeeecees coneenenececeecnees eetitinententinne tittineenenttineens rneetettenietettttty EET Hi HIRT tt Hitt i HATTER pisssssisniuaniiiiag titiiteeterttnitente tinnereenttitintttt: seenertaeene

  24. Slide 24: Since FIM

    soe Since FIM etennssagennnnoe rnnngnnnanagneneneennenneggennnnegenanngennanagnen ana annnennnenennageeennneenennegennnneeeeenanoneenaggeyanegenannegennnneg nanegnennnnegenntt TRIMMER TRROHHHHE HONEA EEN HReHNRRTHE HHH nt Ne HANES HHRHHSHR HH HEHEHE att i Hinenineaen eureneateriye areneeraresieeerar

  25. Slide 25: Employee Issues

    ———_— TRIVASCULA R* Employee Issues :

  26. Slide 26: Organization and talent

    Organization and talent No decisions on employment will be made or communicated until after the merger is completed (Q1 2016) Antitrust laws require that we continue to function as independent competing companies until the merger is complete – Business as usual Endologix has indicated that Santa Ros

  27. Slide 27: Benefits and compensation

    Benefits and compensation Merger Agreement requires compensation and benefits at least as favorable as what you have now for one year Endologix required to honor eligibility and years of service (vacation, PTO) Open Enrollment – TRIV Health Plan will remain in place through early 2016 ESPP – will be

  28. Slide 28: Benefits

    Benefits Conversion to new benefits Q2 2016 Benefits at least as good as current plans to include Kaiser, Blue Shield PPO, HMO & HSA Post merger, harmonization of PTO and Vacation programs – all accrued & unused PTO will roll over Generally Endologix PTO and Holiday plans are in line or slightly bet

  29. Slide 29: What to expect in coming weeks

    What to expect in coming weeks Meeting with John McDermott, Endologix CEO, this Friday Regular communications from Chris Chavez and others on the status of the upcoming merger Communications and educational forums for stock option, RSU, ESPP and benefits questions and transition Business as usual. K

  30. Slide 30: Deal Structure

    ——__ TRIVASCULA R* Deal Structu reiov ia F, .

  31. Slide 31: Deal structure

    Deal structure Principally a stock-for-stock transaction Each share of TRIV stock will be exchanged for a fraction of a share of ELGX stock Fractional shares will be paid in cash TRIV Shareholders will receive cash proceeds based on the gross value of in the money options, warrants, convertible debt

  32. Slide 32: Share price determination

    Share price determination Representative Calculation of Per Share Value ELGX share price 10/23 $ 13.81 Share exchange ratio (0.5832x) $ 8.05 Cash per share 1.05 Implied per share value $ 9.10 ELGX share price will fluctuate Exchange ratio will fluctuate based on ELGX shares outstanding TRIV Sharehol

  33. Slide 33: Options & RSU’s

    Options & RSU’s All outstanding Options and RSU’s will vest prior to close Employees will have a window to exercise “in-the-money” options Exercised options and RSU’s will receive ELGX stock + cash consideration at close Unexercised options will be canceled

  34. Slide 34: Mechanics of transaction

    Mechanics of transaction Owned Stock RSU In-the-money Options Accelerated Vesting/ Exercise TRIV Stock ELGX Stock ELGX Stock Cash Cash

  35. Slide 35: Wrap-up

    ———_— TRIVASCULA R* Wrap-up ws ~*~

  36. Slide 36: Highlights of our future merged company: benefits to key stakeholders

    Highlights of our future merged company: benefits to key stakeholders Patients Customers Employees Investors Broadest indications for more on-label treatments Complex AAA and TAA solutions Enabling individualized AAA treatment Aortic innovation leader with 370 patents and robust pipeline Broadest po

  37. Slide 37: Timing/next steps

    Timing/next steps Now – Deal Close ? Continue to operate as independent competitors ? Integration planning (primarily by Endologix) ? Communications regarding intended organization ? Employees ? Customers ? Suppliers ? Partners Post Deal Close ? Begin integration process ? Clarify new roles in organ

  38. Slide 38: Forward-Looking Statements

    Forward-Looking Statements: This communication includes statements that may be forward-looking statements. The words “believe,” “expect,” “anticipate,” “project” and similar expressions, among others, generally identify forward-looking statements. Endologix and TriVascular caution that these forward

  39. Slide 39: Additional Information and Where to Find It

    Additional Information and Where to Find It: The transaction referenced in this communication has not yet commenced, and no proxies are yet being solicited. Endologix plans to file a registration statement on Form S–4 (“S-4”) that will serve as a prospectus for Endologix shares to be issued as consi

TriVascular Technologies — Merger or Acquisition (October 2015) on 6ix